BURLINGAME, Calif. & CALGARY, Alberta--(BUSINESS WIRE)--Parvus Therapeutics, a biopharmaceutical company focused on the development of disease-specific immunoregulatory medicines to treat autoimmune ...

CALGARY, Alberta--(BUSINESS WIRE)--Parvus Therapeutics, a biopharmaceutical company developing disease-modifying nanomedicines to halt or reverse autoimmune disease without causing general immune ...

SALT LAKE CITY, UT--(Marketwire - Mar 18, 2013) - Eurotech subsidiary Parvus Corporation announces that the DuraCOR 830, a rugged tactical mission processor subsystem based on an ultra-low power Intel ...

Genentech, a member of the Roche Group, today launched an up-to-$800 million partnership with Parvus Therapeutics to develop, manufacture, and commercialize new treatments for inflammatory bowel ...

Genentech has teamed up with Parvus Therapeutics to develop immune tolerance drugs. The Roche subsidiary put together an $800 million-plus deal to work with Parvus on drugs to treat autoimmune ...

Canada’s Parvus Therapeutics has signed a deal with Roche’s Genentech unit to develop, manufacture and market drugs for inflammatory bowel disease, autoimmune liver diseases, and coeliac disease. The ...

SALT LAKE CITY, UT--(Marketwired - Apr 16, 2013) - Parvus Corporation, a Eurotech subsidiary and Cisco Systems Solution Technology Integration (STI) partner, announces it has signed a teaming ...

Novartis, which has had a busy week for its CAR-T and NASH programs, today moved onto diabetes after penning a new pact with virtual Canadian biotech Parvus Therapeutics to use its leading tech. Exact ...

MILAN, June 24 (Reuters) - Parvus Asset Management Europe, a major UBI shareholder, will decide whether to accept Intesa Sanpaolo's takeover offer for the Italian bank after publication of the ...

The founders of London-based hedge fund Parvus Asset Management like to play their cards close to their chest. By showing their hand in a recent investment, they thwarted a proposed merger of gambling ...